Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENTHRANE vs ABILIFY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Penthrane (methoxyflurane) is a volatile halogenated ether anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and central nervous system depression. It also sensitizes the myocardium to catecholamines and produces nephrotoxic fluoride ions via metabolism.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Induction and maintenance of general anesthesia,Analgesia for short-duration procedures (off-label)
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
0.2-0.5% inspired concentration via inhalation for analgesia; for general anesthesia, up to 2% inspired via vaporizer.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
Terminal elimination half-life ranges from 1.5 to 4 hours, reflecting slow washout due to high fat solubility and prolonged release from adipose tissue. Clinically, this can lead to prolonged sedation and risk of fluoride-induced nephrotoxicity.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Primarily hepatic via cytochrome P450 enzymes (CYP2E1), releasing inorganic fluoride ions; approximately 50% is metabolized.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Approximately 50% of absorbed methoxyflurane is eliminated unchanged by the lungs; the remainder is metabolized, primarily via hepatic CYP450 isoenzymes, with fluoride ion and other metabolites excreted renally. Biliary/fecal elimination is negligible (<1%).
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
40–50% bound to plasma proteins, primarily albumin.
>99% bound to albumin and alpha-1-acid glycoprotein.
Vd approx 2.0–3.5 L/kg, reflecting extensive distribution into adipose tissue and slow equilibration.
4.9 L/kg (high distribution into tissues).
Inhalation: 100% via pulmonary route (no first-pass metabolism). Not administered orally or parenterally in clinical use.
Oral: 87% (tablet and solution); IM: 100%.
No specific GFR-based dose adjustments; use with caution in severe renal impairment due to potential nephrotoxicity from fluoride ions.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment due to potential hepatotoxicity.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Not recommended for children due to risk of nephrotoxicity and hepatotoxicity; alternative agents preferred.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Use lower inspired concentrations (e.g., 0.2-0.5%) and monitor closely for hypotension and respiratory depression; consider reduced dose due to decreased renal and hepatic function.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
Not approved for use in the United States; has been associated with fatal hepatotoxicity and nephrotoxicity, particularly when used at high doses or for prolonged periods.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
Hepatotoxicity and nephrotoxicity due to fluoride ion accumulation; myocardial sensitization to catecholamines; malignant hyperthermia risk; respiratory depression; dose-dependent renal impairment.
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Hypersensitivity to halogenated anesthetics; known or suspected susceptibility to malignant hyperthermia; significant hepatic or renal impairment; concurrent use of nephrotoxic agents.
Known hypersensitivity to aripiprazole or any of its excipients.
No direct food interactions are documented. However, methoxyflurane metabolism may be affected by hepatic enzyme inducers or inhibitors. Avoid excessive consumption of grapefruit juice as it may inhibit CYP2E1, potentially altering drug metabolism. Maintain adequate hydration to help reduce the risk of nephrotoxicity.
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
First trimester: Limited human data; animal studies show fetal toxicity at high doses. Potential risk of congenital anomalies cannot be excluded. Second and third trimesters: May cause fetal hypotension and bradycardia; avoid prolonged or high-dose exposure. Near term: Risk of neonatal respiratory depression.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Unknown if excreted in human milk. M/P ratio not established. Caution advised; consider benefits of breastfeeding vs. potential risk to infant.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
No specific dose adjustments recommended due to limited data. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy; use lowest effective dose for shortest duration.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
Penthrane (methoxyflurane) is a volatile inhalational anesthetic with potent analgesic properties at subanesthetic doses. It is primarily used for emergency pain relief via a handheld inhaler (Penthrox). Key clinical pearls: (1) Nephrotoxicity is dose-dependent due to inorganic fluoride metabolites; limit exposure to a maximum of 6 m L over a week. (2) Avoid concurrent use of tetracyclines or aminoglycosides due to increased nephrotoxic risk. (3) Caution in patients with renal impairment, hepatic disease, or malignant hyperthermia susceptibility. (4) Rapid onset of analgesia within 2-5 breaths; monitor for excessive sedation or respiratory depression. (5) Do not use in patients with cardiovascular instability or hypovolemia as it can cause myocardial depression.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
Penthrane is used to relieve moderate to severe pain from trauma or procedures.,Inhale from the device as instructed; do not swallow the liquid.,You may feel drowsy or dizzy; avoid driving or operating machinery for at least 24 hours after use.,Do not consume alcohol or take other central nervous system depressants without consulting your doctor.,Report any signs of kidney injury such as decreased urination, swelling, or fatigue.,Use only as directed and do not exceed the prescribed dose or duration.,Keep the inhaler out of reach of children and do not share with others.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENTHRANE vs ABILIFY, answered by our medical review team.
PENTHRANE is a Inhaled Anesthetic that works by Penthrane (methoxyflurane) is a volatile halogenated ether anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and central nervous system depression. It also sensitizes the myocardium to catecholamines and produces nephrotoxic fluoride ions via metabolism.. ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENTHRANE and ABILIFY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENTHRANE is: 0.2-0.5% inspired concentration via inhalation for analgesia; for general anesthesia, up to 2% inspired via vaporizer.. The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENTHRANE and ABILIFY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENTHRANE is classified as Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Potential risk of congenital anomalies cannot be excluded. Second and third trimesters: May c. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.